142 related articles for article (PubMed ID: 35699480)
21. Molecular profile of grade 3 endometrioid endometrial carcinoma: is it a type I or type II endometrial carcinoma?
Alvarez T; Miller E; Duska L; Oliva E
Am J Surg Pathol; 2012 May; 36(5):753-61. PubMed ID: 22498825
[TBL] [Abstract][Full Text] [Related]
22. Massively Parallel Sequencing-Based Clonality Analysis of Synchronous Endometrioid Endometrial and Ovarian Carcinomas.
Schultheis AM; Ng CK; De Filippo MR; Piscuoglio S; Macedo GS; Gatius S; Perez Mies B; Soslow RA; Lim RS; Viale A; Huberman KH; Palacios JC; Reis-Filho JS; Matias-Guiu X; Weigelt B
J Natl Cancer Inst; 2016 Jun; 108(6):djv427. PubMed ID: 26832770
[TBL] [Abstract][Full Text] [Related]
23. Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma.
García-Sanz P; Triviño JC; Mota A; Pérez López M; Colás E; Rojo-Sebastián A; García Á; Gatius S; Ruiz M; Prat J; López-López R; Abal M; Gil-Moreno A; Reventós J; Matias-Guiu X; Moreno-Bueno G
Int J Cancer; 2017 Apr; 140(7):1551-1563. PubMed ID: 27997699
[TBL] [Abstract][Full Text] [Related]
24. Recurrence patterns and prognostic factors in lymphovascular space invasion-positive endometrioid endometrial cancer surgically confined to the uterus.
Sahin H; Meydanli MM; Sari ME; Kocaman E; Cuylan ZF; Yalcin I; Coban G; Özen Ö; Sirvan L; Güngör T; Ayhan A
Taiwan J Obstet Gynecol; 2019 Jan; 58(1):82-89. PubMed ID: 30638487
[TBL] [Abstract][Full Text] [Related]
25. β-Catenin mutations in recurrent FIGO IA grade I endometrioid endometrial cancers.
Myers A; Barry WT; Hirsch MS; Matulonis U; Lee L
Gynecol Oncol; 2014 Aug; 134(2):426-7. PubMed ID: 24952365
[No Abstract] [Full Text] [Related]
26. Ultrastaging of 'negative' pelvic lymph nodes in patients with low- and intermediate-risk endometrioid endometrial cancer who developed non-vaginal recurrences.
Gill SE; Garzon S; Multinu F; Hokenstad AN; Casarin J; Cappuccio S; McGree ME; Weaver AL; Cliby WA; Keeney GL; Mariani A
Int J Gynecol Cancer; 2021 Dec; 31(12):1541-1548. PubMed ID: 34706876
[TBL] [Abstract][Full Text] [Related]
27. Integrative Protein-Based Prognostic Model for Early-Stage Endometrioid Endometrial Cancer.
Yang JY; Werner HM; Li J; Westin SN; Lu Y; Halle MK; Trovik J; Salvesen HB; Mills GB; Liang H
Clin Cancer Res; 2016 Jan; 22(2):513-23. PubMed ID: 26224872
[TBL] [Abstract][Full Text] [Related]
28. Aberrant nuclear β-catenin distribution does not prognosticate recurrences of endometrioid endometrial cancers - A retrospective single-institutional study.
Beshar I; Moon AS; Darji H; Liu C; Jennings MT; Dorigo O; Litkouhi B; Diver EJ; Karam AK; Howitt BE; Renz M
Gynecol Oncol; 2023 Dec; 179():85-90. PubMed ID: 37944330
[TBL] [Abstract][Full Text] [Related]
29. Endometrial Carcinoma Diagnosis: Use of FIGO Grading and Genomic Subcategories in Clinical Practice: Recommendations of the International Society of Gynecological Pathologists.
Soslow RA; Tornos C; Park KJ; Malpica A; Matias-Guiu X; Oliva E; Parkash V; Carlson J; McCluggage WG; Gilks CB
Int J Gynecol Pathol; 2019 Jan; 38 Suppl 1(Iss 1 Suppl 1):S64-S74. PubMed ID: 30550484
[TBL] [Abstract][Full Text] [Related]
30. Low-grade, low-stage endometrioid endometrial adenocarcinoma: a clinicopathologic analysis of 324 cases focusing on frequency and pattern of myoinvasion.
Quick CM; May T; Horowitz NS; Nucci MR
Int J Gynecol Pathol; 2012 Jul; 31(4):337-43. PubMed ID: 22653347
[TBL] [Abstract][Full Text] [Related]
31. [Significance of phosphoinositide 3 kinase/AKT pathway alterations in endometrial carcinoma].
Yang X; Dong Y; Zhang XM; Liang Y; Zhang Y; Meng YT; Wang Y; Wang W; Nong L; Li T; Liao QP
Zhonghua Bing Li Xue Za Zhi; 2011 Dec; 40(12):799-804. PubMed ID: 22336203
[TBL] [Abstract][Full Text] [Related]
32. [Significance of prognostic evaluation of International Federation of Gynecology and Obstetrics 2009 staging system on stage I endometrioid adenocarcinoma].
Wang ZQ; Zhang Y; Wang JL; Shen DH; Mu T; Zhao X; Yao YY; Bai Y; Wei LH
Zhonghua Fu Chan Ke Za Zhi; 2012 Jan; 47(1):33-9. PubMed ID: 22455691
[TBL] [Abstract][Full Text] [Related]
33. Patterns of recurrence in 1988 FIGO stage IC endometrioid endometrial cancer.
Long KC; Zhou Q; Hensley ML; Alektiar KM; Gomez J; Gardner GJ; Chi DS; Barakat RR; Abu-Rustum NR
Gynecol Oncol; 2012 Apr; 125(1):99-102. PubMed ID: 22112609
[TBL] [Abstract][Full Text] [Related]
34. Lynch syndrome--related endometrial carcinomas show a high frequency of nonendometrioid types and of high FIGO grade endometrioid types.
Carcangiu ML; Radice P; Casalini P; Bertario L; Merola M; Sala P
Int J Surg Pathol; 2010 Feb; 18(1):21-6. PubMed ID: 19443869
[TBL] [Abstract][Full Text] [Related]
35. Genetic and molecular subtype heterogeneity in newly diagnosed early- and advanced-stage endometrial cancer.
Da Cruz Paula A; DeLair DF; Ferrando L; Fix DJ; Soslow RA; Park KJ; Chiang S; Reis-Filho JS; Zehir A; Donoghue MTA; Wu M; Brown DN; Murali R; Friedman CF; Zamarin D; Makker V; Mueller JJ; Leitao MM; Abu-Rustum NR; Aghajanian C; Weigelt B
Gynecol Oncol; 2021 May; 161(2):535-544. PubMed ID: 33622519
[TBL] [Abstract][Full Text] [Related]
36. Clinicopathologic and Immunohistochemical Correlates of CTNNB1 Mutated Endometrial Endometrioid Carcinoma.
Costigan DC; Dong F; Nucci MR; Howitt BE
Int J Gynecol Pathol; 2020 Mar; 39(2):119-127. PubMed ID: 30702464
[TBL] [Abstract][Full Text] [Related]
37. Factors related to recurrence in non-obese women with endometrial endometrioid adenocarcinoma.
Panggid K; Cheewakriangkrai C; Khunamornpong S; Siriaunkgul S
J Obstet Gynaecol Res; 2010 Oct; 36(5):1044-8. PubMed ID: 21058438
[TBL] [Abstract][Full Text] [Related]
38. Clinical impact of genetic alterations of CTNNB1 in patients with grade 3 endometrial endometrioid carcinoma.
Kobayashi Kato M; Asami Y; Takayanagi D; Matsuda M; Shimada Y; Hiranuma K; Kuno I; Komatsu M; Hamamoto R; Matsumoto K; Ishikawa M; Kohno T; Kato T; Shiraishi K; Yoshida H
Cancer Sci; 2022 May; 113(5):1712-1721. PubMed ID: 35278272
[TBL] [Abstract][Full Text] [Related]
39. Clinicopathologic analysis of matched primary and recurrent endometrial carcinoma.
Soslow RA; Wethington SL; Cesari M; Chiappetta D; Olvera N; Shia J; Levine DA
Am J Surg Pathol; 2012 Dec; 36(12):1771-81. PubMed ID: 23154767
[TBL] [Abstract][Full Text] [Related]
40. Understanding the clinical implication of mismatch repair deficiency in endometrioid endometrial cancer through a prospective study.
Kim SR; Tone A; Kim RH; Cesari M; Clarke BA; Eiriksson L; Hart T; Aronson M; Holter S; Lytwyn A; Lajkosz K; Oldfield L; Gallinger S; Bernardini MQ; Oza AM; Djordjevic B; Lerner-Ellis J; Van de Laar E; Vicus D; Pugh T; Pollett A; Ferguson SE
Gynecol Oncol; 2021 Apr; 161(1):221-227. PubMed ID: 33478752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
